Significant Weight Loss in a Patient Taking Olmesartan: An Unusual Case Report.

Andromachi Makri, Matilda Florentin, Moses S Elisaf, George Liamis

Abstract readCase Reports

In one paragraph

Article in Current drug safety, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Comparison of Adverse Events Among Angiotensin Receptor Blockers in Hypertension Using the United States Food and Drug Administration Adverse Event Reporting System.Cureus · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andromachi MakriDepartment of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.

Matilda FlorentinDepartment of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.

Moses S ElisafDepartment of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.

George LiamisDepartment of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveOlmesartan-induced enteropathy consists a syndrome that mimics celiac disease both clinically and histologically. Cases of this entity have sporadically been reported since 2012 and are usually characterized by severe diarrhea and malabsorption, followed by significant weight loss. CASE REPORT: Herein, we report an uncommon case of this syndrome, where weight loss preceded several months the onset of gastrointestinal symptoms. DISCUSSION AND

conclusionPhysicians should be aware of unexplained weight loss in patients taking olmesartan, as prompt discontinuation of the drug may prevent the deleterious consequences of malabsorption.

Indexed as

Weight LossAgedAntihypertensive AgentsDiarrheaFemaleHumansHypertensionImidazolesTetrazolesAntihypertensive AgentsImidazolesolmesartanTetrazolesARBcomputed tomographyEnteropathyIgAolmesartanweight loss.

Identifiers

PMID30848210

DOI10.2174/1574886314666190307142111

PMCPMC6865051

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.